1. Home
  2. EDIT

EDIT

Editas Medicine Inc.

Logo Editas Medicine Inc.

Health Care

Biotechnology: Biological Products (No Diagnostic Substances)

Nasdaq

as 04-23-2024 2:24pm EST

$
-
.
-
-
+$
-
.
-
-
+
-
.
-
-
%

Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.

Founded: 2013 Country:
United States
United States
Employees: N/A City: CAMBRIDGE
Market Cap: 451.5M IPO Year: 2016
Target Price: $14.27 AVG Volume (30 days): 1.9M
Analyst Decision: Buy Number of Analysts: 12
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -2.02 EPS Growth: N/A
52 Week Low/High: $6.08 - $11.91 Next Earning Date: 05-03-2024
Revenue: $78,123,000 Revenue Growth: 296.32%
Revenue Growth (this year): -52.51% Revenue Growth (next year): -20.27%

Share on Social Networks: